This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, South Africa or any jurisdiction in which the same would be unlawful. This announcement is not an offer of securities in the United States, Canada, South Africa, Australia, Japan or any jurisdiction in which the same would be unlawful.
The new storage facility in Niel, BelgiumToday, Cryo-Save opened a new high-tech laboratory in the research park Waterfront in Niel near Antwerp. Cryo-Save specializes in research into adult stem cells and their long-term storage for medical therapeutic use. The new laboratory facility will be capable of storing up to 1 million samples and is the largest stem cell bank in Europe. The investment amounts to almost €6 million.
25,000 samples per year
Revenues up 52%, profits up 17%
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading adult stem cell storage bank, has published interim results for the six months ended 30 June 2009.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, plans to seek an additional listing on Euronext Amsterdam in the fourth quarter of the current financial year to complement the Group’s shares being traded on AIM in London. Cryo-Save was admitted to trading on AIM on 6 November 2007.
Cryo-Save intends to review the need to maintain the AIM listing in early 2010.
The Board of Cryo-Save announces that, pursuant to authorities granted by shareholders at the Company’s Annual General Meeting held on 20 May 2009, the Company purchased 100,000 Ordinary Shares of Euro 0.02 (“Ordinary Shares”) at a price of 52.5 pence per share to be held in Treasury on 13 August 2009.
Notice of Interim Results – 15 September 2009
Cryo-Save Group NV, (AIM: CRYO, ‘the Company’), Europe’s largest adult stem cell storage bank, will be publishing its Interim Results for the six months ended 30 June 2009 on Tuesday, 15 September 2009.
Completion of Acquisition of Italian service company
Further to the announcement made on 27 May 2009, Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, is pleased to announce the completion of the acquistion of Salus Futura Ltd, which holds all shares of Salus Futura Srl, Italy (“Salus Futura”), following the signing of the sale and purchase agreement and transfer of the initial consideration of €0.4 million in return for Salus Futura shares on 10 July 2009.
Most successful quarter in history – 7,000 samples stored in Q2 2009, 11% up on Q1 2009
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, has published its Q2 2009 sample storage numbers for the quarter to 30 June 2009.
7,000 samples were stored in Q2 2009, up 11% over Q1 2009 (6,300 samples) and up 6% over Q2 2008 (6,600 samples), which was the Group’s best quarter in history.
Distribution agreement signed with leading Iberian medical services provider extends reach in Spain and Portugal
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, has signed an exclusive distribution agreement for the Iberian market with the Spanish subsidiary of Labco, a leading pan European medical diagnostic labs network. As a result of this agreement, Cryo-Save will further strengthen its leadership position in Spain and have an additional channel to market in Portugal.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, announces that Rob Koremans has resigned in order to take up a senior position with a leading pharmaceutical company. He will leave the Group at the end of July at which time Marc Waeterschoot, the founder and former Chief Executive and currently Chairman, will become interim Chief Executive. Rob continues to be an advisor to the Group.